1 week Ago By ABMN Staff
Renaissance Technologies LLC trimmed its holdings in Gossamer Bio, Inc. ( NASDAQ:GOSS – Free Report ) by 1.9% in the fourth quarter, according to its most recent disclosure with the SEC.
The fund owned 1,712,503 shares of the company’s stock after selling 32,302 shares during the period. Renaissance Technologies LLC owned 0.76% of Gossamer Bio worth $1,549,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its holdings in shares of Gossamer Bio by 1.
1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company’s stock valued at $1,123,000 after buying an additional 13,902 shares during the last quarter.
Smith Moore & CO. boosted its holdings in Gossamer Bio by 32.7% in the 4th quarter.
Smith Moore & CO. now owns 300,000 shares of the company’s stock valued at $271,000 after purchasing an additional 74,000 shares in the last quarter. Monaco Asset Management SAM increased its position in Gossamer Bio by 39.
5% during the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock worth $4,859,000 after purchasing an additional 1,520,721 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Gossamer Bio by 1.
7% during the 4th quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company’s stock worth $2,037,000 after buying an additional 38,084 shares in the last quarter. 81.
23% of the stock is owned by hedge funds and other institutional investors. Analysts Set New Price Targets A number of brokerages recently weighed in on GOSS. Wedbush reaffirmed an “outperform” rating and set a $4.
00 price objective on shares of Gossamer Bio in a report on Friday, March 14th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a report on Tuesday, March 18th.
Finally, The Goldman Sachs Group dropped their price objective on Gossamer Bio from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday, April 17th.
Gossamer Bio Stock Down 2.1 % Shares of NASDAQ:GOSS opened at $0.96 on Monday.
The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.
64. Gossamer Bio, Inc. has a 52-week low of $0.
50 and a 52-week high of $1.55. The stock’s fifty day simple moving average is $1.
10 and its 200-day simple moving average is $0.98. The company has a market capitalization of $217.
75 million, a P/E ratio of -2.99 and a beta of 1.88.
Gossamer Bio ( NASDAQ:GOSS – Get Free Report ) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.
15). The company had revenue of $9.38 million during the quarter, compared to analysts’ expectations of $7.
02 million. As a group, equities research analysts forecast that Gossamer Bio, Inc. will post -0.
28 earnings per share for the current fiscal year. About Gossamer Bio ( Free Report ) Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Featured Articles Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter ..
